Three grantees will research treatment and disparities among patients with advanced pancreatic and breast cancers.
The American Cancer Society and Flatiron Health announced today that the 2021 Real-World Data Impact Awards will support research into health disparities among patients with advanced pancreatic and breast cancer.
This year marks the third year of the joint grant-making program, under which ACS-funded researchers have the opportunity to apply for additional funding and access to Flatiron real-world data.
Eligible applicants are ACS awardees experienced in health-services and observational research who are encouraged to submit proposals that address health disparities.
The 2021 grants have been awarded to:
Shannon Lynch, PhD, MPH, assistant professor, Cancer Prevention and Control at Fox Chase Cancer Center. She will study patients with metastatic pancreatic cancer, investigating possible differences in time to first treatment, number of lines of chemotherapy, first and second line therapy regimens, and hospice use by race, ethnicity and insurance status.
Dawn Hershman, MD, MS, FASCO, professor of Medicine and Epidemiology at Columbia University, who will study how the use, toxicity, and efficacy of oral antineoplastic drugs impacts Black and Hispanic patients, compared to Non-Hispanic-white patients, with advanced breast cancer.
- Roger Anderson, PhD, professor of Medicine at the University of Virginia, who will explore patterns of care related to tumor, patient, and demographic characteristics focused on the use of CDK4/6i for hormone-receptor-positive patients with metastatic breast cancer.
"Flatiron Health is honored to partner with ACS to leverage Flatiron's EHR-derived real-world data to advance research toward better and more equitable cancer treatments and outcomes," said Rebecca Miksad, MD, MPH, senior medical director at Flatiron Health. "RWD can help the field learn more about health disparities to inform effective action to address them."
The 2021 Real-World Data Impact Award grantees will each receive $75,000 and access to a Flatiron de-identified dataset derived specific to their research questions from the health records of patients with cancer treated in both community clinics and academic medical centers. Additionally, awardees will have access to Flatiron and ACS clinical and methodological experts.
Recipients of the 2020 Real-World Data Impact Awards, including Siran M. Koroukian-Hajinazarian, PhD, and Kale Minal, MD, recently had research published in ASCO's Journal of Clinical Oncology and AACR's Cancer Epidemiology, Biomarkers & Prevention, respectively.
The joint grant-making program supports Flatiron's and ACS' goals of accelerating cancer research and improving treatment and outcomes for patients.
Flatiron Health is a health tech company dedicated to delivering better care for patients today and tomorrow. Through clinical and data science, it translates patient experiences into real-world evidence to improve treatment, inform policy, and advance research. It is an independent affiliate of the Roche Group.